logo
Share SHARE
FONT-SIZE Plus   Neg

Baxter, Halozyme Issue Update On HyQ Biologics License Application

Baxter International Inc. (BAX) and Halozyme Therapeutics, Inc. (HALO) announced that the U.S. Food and Drug Administration, or FDA, is requesting additional information to complete its review of the HyQ Biologics License Application, or BLA.

Both the companies will work closely together to develop studies to provide additional data to address concerns raised by the FDA related to the long-term chronic use of HyQ. At present, the companies expect to participate in a meeting of the FDA's Blood Products Advisory Committee concerning the agency's request for additional data. The companies expect these requests to require additional time to complete and to delay their anticipated regulatory review and approval timeline.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
While Democrats have largely been critical of the Republican tax reform plan, President Donald Trump has claimed the proposal has some bipartisan support. Trump suggested to reporters ahead of a meeting with members of the Senate Finance Committee on Wednesday that "people on both sides" support the tax reform plan. Healthcare is very expensive in the U.S., in fact among the most expensive in the world by most measures. Health care facilities are largely owned and operated by businesses in the private sector. Most Americans have access to health care, though costs and services vary from state to state. However,... Electronic Arts Inc. said it is shutting down its Visceral Games Studio and making major changes to its upcoming Star Wars project currently being developed by the studio. Visceral Games is best known for creating the "Dead Space" series.
comments powered by Disqus
Follow RTT